Acetone

Acetone

SCHEMBL4847604

CC(C)=O.COC(C)(C)OC

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
ALDH1A1 P00352 5/20 0.41
TSHR P16473 3/20 0.33
GAA P10253 2/20 0.32
DGAT1 O75907 1/20 0.32
MGAM O43451 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
THPO P40225 1/20 0.31
FFAR3 O14843 1/20 0.31
LCK P06239 1/20 0.31
FYN P06241 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetone SCHEMBL1822236 0.81 ALDH1A1 (0.61) LMNAALDH1A1TSHRGAADGAT1
Methyl Alcohol SCHEMBL6261246 0.81
SCHEMBL49039 0.80
Acetone SCHEMBL11778591 0.79 LMNA (0.43) LMNAALDH1A1TSHRGAADGAT1
SCHEMBL298347 0.78
SCHEMBL29989468 0.76
Hydrochloric Acid SCHEMBL27895817 0.76
Hypophosphorous Acid SCHEMBL11214397 0.76 ALDH1A1 (0.35) ALDH1A1
SCHEMBL19859132 0.76 TSHR (0.67) LMNAALDH1A1TSHR
Cyclohexane SCHEMBL2480141 0.73 ALDH1A1 (0.50) LMNAALDH1A1TSHRDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5200516-A Synthesis of sugars from substituted and unsubstituted arene diols VIRGINIA TECH INTELLECTUAL PROPERTIES (US) 1993-04-06 US claimed
US-20200281944-A1 Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders PIRAEE MAHMOOD (CA) 2020-09-10 US disclosed
CN-107207515-B Pyrazine compounds for the treatment of infectious diseases 豪夫迈·罗氏有限公司 2019-05-28 CN disclosed
CN-106377540-A Bifunctional compounds binding to adenosine A2A receptors and adenosine transporters for the prevention and treatment of neurodegenerative diseases 中央研究院 2017-02-08 CN disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
WO-2008009138-A1 CHLOROGENIC ACID DERIVATIVES AND THEIR USE AS ANTI-FUNGAL AGENTS GENESIS GROUP INC. (CA) 2008-01-24 WO disclosed
EP-1704161-A1 HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS Endorecherche, Inc. (CA) 2006-09-27 EP disclosed
EP-1618119-A2 PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS CHIRON CORPORATION (US) 2006-01-25 EP disclosed
EP-1572710-A2 ANTIVIRAL NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-09-14 EP disclosed
WO-2005066194-A1 HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS ENDORECHERCHE, INC. (CA) 2005-07-21 WO disclosed
US-6054478-A PREVENTION OR CURE OF FUNGAL DISEASES IN HUMANS AND ANIMALS;PREPARED BY BIIOTRANSFORMATION GLAXO WELLCOME S.A. (ES) 2000-04-25 US disclosed
US-5952334-A SORDARIN DERIVATIVES; FUNGICIDES GLAXO WELLCOME S.A. (ES) 1999-09-14 US disclosed
EP-0753001-B1 ANTIFUNGAL SORDARIDIN DERIVATIVES GLAXO WELLCOME SA (ES) 1999-09-08 EP disclosed
EP-0791007-B1 ANTIFUNGAL SORDARIDIN DERIVATIVES GLAXO WELLCOME SA (ES) 1999-08-11 EP disclosed
US-5854280-A Antifungal sordaridin derivatives GLAXO WELLCOME S.A. (ES) 1998-12-29 US disclosed
EP-0791007-A1 ANTIFUNGAL SORDARIDIN DERIVATIVES Glaxo Wellcome S.A. (ES) 1997-08-27 EP disclosed
WO-1996014327-A1 ANTIFUNGAL SORDARIDIN DERIVATIVES GLAXO WELLCOME S.A. (ES) 1996-05-17 WO disclosed
EP-0711783-A1 Antifungal Sordarin derivatives GLAXO, S.A. (ES) 1996-05-15 EP disclosed
US-5173510-A Anticholesterol agents AMERICAN CYANAMID COMPANY (US) 1992-12-22 US disclosed
US-5053426-A Enzyme inhibitors AMERICAN CYANAMID COMPANY (US) 1991-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200281944-A1 Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders CYP46A1, LSS, CYP27A1 LMNA 159/4885ALDH1A1 3533/4885TSHR 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.